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Background: Detailed and systematic understanding of the biological effects of millions of available compounds
on living cells is a significant challenge. As most compounds impact multiple targets and pathways, traditional
methods for analyzing structure-function relationships are not comprehensive enough. Therefore more advanced
integrative models are needed for predicting biological effects elicited by specific chemical features. As a step
towards creating such computational links we developed a data-driven chemical systems biology approach to
comprehensively study the relationship of 76 structural 3D-descriptors (VolSurf, chemical space) of 1159 drugs with
the microarray gene expression responses (biological space) they elicited in three cancer cell lines. The analysis
covering 11350 genes was based on data from the Connectivity Map. We decomposed the biological response
profiles into components, each linked to a characteristic chemical descriptor profile.
Results: Integrated analysis of both the chemical and biological space was more informative than either dataset
alone in predicting drug similarity as measured by shared protein targets. We identified ten major components that
link distinct VolSurf chemical features across multiple compounds to specific cellular responses. For example,
component 2 (hydrophobic properties) strongly linked to DNA damage response, while component 3 (hydrogen
bonding) was associated with metabolic stress. Individual structural and biological features were often linked to one
cell line only, such as leukemia cells (HL-60) specifically responding to cardiac glycosides.
Conclusions: In summary, our approach identified several novel links between specific chemical structure
properties and distinct biological responses in cells incubated with these drugs. Importantly, the analysis focused
on chemical-biological properties that emerge across multiple drugs. The decoding of such systematic relationships
is necessary to build better models of drug effects, including unanticipated types of molecular properties having
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The mechanism of action of drugs at the biochemical
level has typically been studied by investigating specific
chemical properties of the drug and the biological prop-
erties of its specific target [1,2]. This is the standard
paradigm in Quantitative Structure Activity Relationship
(QSAR) studies, where multivariate mathematical mod-
els are used for modeling the relationships between a set
of physiochemical or structural properties and biological
activity. In previous QSAR studies, such as in the clas-
sical 3D-QSAR work by Cramer et al. [3], values of a
single biological activity measure are predicted.
However, biological responses at the cellular level are
diverse and each drug typically binds to a multitude of
targets in the cells and elicits a number of other off-
target effects. Systems-level approaches are thus needed
to get a more comprehensive view of drug effects in liv-
ing cells. Genome-wide massively multivariate descrip-
tion of the cellular responses caused by the drugs, such
as in the Connectivity Map program (CMap; Lamb
et al., [4]), requires new kinds of tools for analysis and
interpretation.
Chemical systems biology has emerged at the interface
of systems biology and chemical biology with the goal ofFigure 1 Data-driven search for statistical relationships between Chem
(gene expression).constructing a systems-level understanding of drug
actions. Systematic analysis of a network of drug effects,
i.e. network pharmacology, offers great opportunities for
drug design in the future [5]. Chemical systems biology
has also been used to predict drug side effects [6] as well
as in other types of toxicological analysis [7].
Here, we undertook a complementary approach, by
studying the impact of a host of chemical descriptors
across a large panel of drugs on the biological response
profiles measured at a genome-wide scale. We linked
key structural components of the drug molecules, as
defined by 3D VolSurf descriptors, with the consistent
biological properties, as measured by microarray gene
expression profiles. We developed a data-driven ap-
proach to analyze relationships between patterns of
chemical descriptors of the drugs on one hand, and
matching patterns in the cellular responses measured by
genome-wide expression profiles, as shown in Figure 1.
As biological response data we used the Connectivity
Map (CMap, [4,8]), which consists of gene expression
measurements from three cancer cell lines (MCF7-
breast, PC3-prostate and HL60-blood) treated with over
a thousand different drug molecules (Figure 1C). These
data offer a unique view to the genome-wide responsesical space (formed of VolSurf features) and Drug response space
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new biological links e.g. between heat shock protein
inhibitors, proteasome inhibitors, and topoisomerase
inhibitors [8].
Our key assumption is that the chemical structure as
encoded in the 3D descriptors of drugs impacts on the
drug response resulting in specific patterns of gene ex-
pression. Furthermore, if there is any statistical relation-
ship between the occurrence of patterns in the chemical
space and the patterns in biological response space,
those patterns are informative in forming hypotheses on
the mechanisms of drug action. Given proper controls,
the statistical responses can be attributed to the specific
features of the chemicals tested out of a diverse drug li-
brary. In this paper we used comprehensive but readily
interpretable models for finding the statistical dependen-
cies. We searched for distinct components that correlate
the patterns in the chemical space with the biological re-
sponse space. Assuming linear relationships, the task
reduces to Canonical Correlation Analysis (CCA [9]) for
searching for correlated components from the two data
spaces (Figure 1D). We visualized the components in a
comprehensive way to facilitate interpretation (Figure 1E
and 1F) and validate them both qualitatively and
quantitatively.
Canonical Correlation Analysis was recently used for
drug side effect prediction and drug discovery by Atias
and Sharan [10]. They applied CCA to combine known
side effect associations of drugs with (i) 2D structure fin-
gerprints and (ii) bioactivity profiles of the chemicals.
The CCA results from both combinations were then
successfully used to predict side effects for the drugs,
suggesting that CCA is effective in finding relevant com-
ponents from heterogeneous data sources.
Drugs generally act on a multitude of direct and
intended targets as well as on a number of non-specific
off-targets. All these targets and effects together connect
to a phenotypic response. As most of these effects are
still poorly understood, modelling of the structure-
target-response profiles across a large drug library is an
important, but challenging goal. In this study we mod-
elled the structure-response relationships of 1159 drug
molecules directly, with CCA components playing the
role of unknown mechanistic processes.
The lack of information on all of the possible targets
prompted us to select a particular set of chemical
descriptors that allows capturing of generic response
patterns. Many kinds of chemical descriptors are avail-
able for characterizing chemical structures in a quantita-
tive way. Simple classical 2D fingerprints can be used to
detect close analogs, but they would miss most if not all
scaffold-hopping situations, where the different chemical
entities give rise to similar pharmacophoric properties.
Fingerprints and pure pharmacophoric descriptors requireclearly defined individual targets, which are not known in
many cases. In the present study, we aimed to bridge the
chemical and biological space by using a set of VolSurf
descriptors of the drugs ([11]; Figure 1A) that are ideal for
capturing both structural similarities and general chemical
features, such as solubility and permeation properties
(ADMET: Absorption, Distribution, Metabolism, Excre-
tion and Toxicology properties). Although VolSurf
descriptors are not thought to explain detailed structure-
activity relationships, such as the binding to a single tar-
get, they offer a good overall interpretation of the molecu-
lar shape, hydrogen bonding, lipophilicity, and related
properties, which are more conservative than individual
binding cavities. It has also been shown that shape is a
major factor when trying to find compounds with similar
biological activity but dissimilar 2D structures [12].
The idea of correlating chemical structures with bio-
logical expression was introduced by Blower et al. in [13].
By combining 2D fingerprint data with biological activity
profiles for the chemicals over 60 cancer cell lines (NCI60),
and with steady-state gene expression measurements from
those cell lines before drug treatments, they obtained indir-
ect relationships between chemical substructures and the
gene targets. In a more recent work, Cheng et al., [14]
investigated correlations between the chemical structures,
bioactivity profiles, and molecular targets for a set of 37
chemicals. This small-scale study demonstrated that combi-
nations of biological activity and chemical structure infor-
mation can provide insights into drug action mechanisms
on a molecular level.
By using the direct gene expression responses to a
large set of drug treatments from the Connectivity Map,
along with comprehensive component-level decompos-
ition of response profiles, we are able to make more dir-
ect observations on how compounds impact on cells and
which features of the chemical molecules and the bio-
logical responses are correlated.
Results and discussion
We analysed the 1159 drug treatment gene expression
responses of three cancer cell lines of the Connectivity
Map, with the methods summarized in Figure 1 and
detailed in Methods. The analysis decomposed the rela-
tionship between the “chemical space” and the “bio-
logical space” into components. The chemical space
consists of the selected 76 chemical descriptors of each
drug and the biological space contains gene expression
responses of corresponding drugs. Each component relates
a characteristic statistical gene expression pattern with a
pattern of the drug properties. We will call the components
“CCA components” as the core method is Canonical Cor-
relation Analysis (CCA). In this section we analyse further
the identified components and the statistical relationships
they discovered.
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components
We evaluate the biological relevance of the extracted
CCA components by studying the functional similarity
of drugs associated with each component. In particular
we measure the performance of the component model
in retrieving similar drugs, as indicated by external data
about their function, and compare it to retrieval based
on either the biological or chemical data separately.
Details of the validation procedure are described in
Methods. The mean average precision obtained for the
retrieval task on the four data sets (CCA components,
chemical space, biological space as represented by GSEA
and Gene expression) are plotted in Figure 2.
The results show that retrieval based on the chemical
space, i.e. VolSurf descriptors, performs clearly better
than retrieval based on the biological space (activities of
gene sets and genes), indicating that the chemical infor-
mation is more relevant for evaluating the functional
similarity of the chemicals. The biological space encoded
by gene sets performs similarly to the original gene ex-
pression, indicating that the gene sets are a sensible en-
coding of the biological space; information lost due to
dimensionality reduction is balanced by introduction of
prior biological knowledge in the form of the sets. Fi-
nally, the combined space formed by the CCA compo-
nents shows significantly better retrieval performance
than either of the data spaces separately. The results are
consistent over the range of drugs considered in theFigure 2 Quantitative validation of functional similarity of drug
components. The figure shows the mean average precision for
retrieving functionally similar chemicals as a function of the number
of top chemicals considered. Results are shown for three
representations: CCA (red), Chemical space (green), and Biological
space (GSEA: blue, Gene expression: grey). Error bars show one
standard error of the mean precision.retrieval task. These results show that CCA is able to ex-
tract and combine relevant information about the chem-
ical structure and biological responses of the drugs,
while filtering out biologically irrelevant structural infor-
mation and also biological responses unrelated to the
chemical characteristics.
Response components and their interpretations
We next analyze the top ten CCA components having
the highest significant correlations between the spaces.
Figure 3 summarizes the relationships between the Vol-
Surf descriptors and the gene sets as captured by the
components. Each component is divided into two sub-
components ‘A’ and ‘B’, where in the first, the compounds
have positive canonical score and in the second negative
(the characteristic response patterns are otherwise the
same, details in Methods). For each CCA-subcomponent
the 20 highest-scoring compounds are listed in the Add-
itional file 1: Top_Compounds.xls.
VolSurf descriptors, unlike more typically used 2D or
3D fingerprints and pharmacophores, do not have clear
structural counterparts such as fragments or functional
groups. Therefore, these descriptors are able to group
together compounds with very dissimilar chemical struc-
tures and yet having the same type of chemical proper-
ties. This is especially important in our study since the
same biological activity may not have been created be-
cause of the same biological target protein but because
of another target protein in the same pathway. Within a
pathway, binding cavity properties may change, but gen-
eral descriptors describing the size, lipophilicity, and
shape are more conservative. Therefore VolSurf descrip-
tors are better suited for classifying these aspects of the
compounds.
In the case of the 1st and 2nd components, the selected
VolSurf descriptors are dominated by hydrophobicity
related descriptors. The 3rd component is connected to
hydrogen bonding, polar interactions, and dispersion-
related descriptors. Component 4 is also strongly con-
nected with hydrophobicity related descriptors, besides
the component is influenced by the molecular volume
and surface area. Components 5–7 are mainly connected
to “pharmacophoric” descriptors that are describing dis-
tribution of strong interaction points over the molecular
space. Components 8 and 9 are both strongly influenced
by integy-moments, describing imbalance of either
hydrophobic or hydrophilic areas over the whole mo-
lecular volume. Component 10 is mainly affected by
shape and size-related parameters, and also lipophilic
integy moments.
On the biological space we observe that the enriched
gene sets in component 1 indicate a mitogenic signaling
response. Component 8 appears similar but has an add-
itional link to cell adhesion signaling. Component 4 in
Figure 3 Relationships decomposed into components. “Eye diagram” showing the top 10 significant CCA components ordered by correlation
from top to bottom (middle), VolSurf descriptors (left), and top gene sets (right). The CCA components are shown as circles, with numbers
indicating the decreasing order of canonical correlation and letters A and B indicating subcomponents (A: positive canonical score, B: negative
canonical score). The widths of the curves from the components to VolSurf descriptors and gene sets indicate the strength of the corresponding
associations. For VolSurf descriptors the subcomponent-specific activity is shown, whereas for the gene sets we show the overall activity in the
component. For an example compound, VolSurf fields are illustrated in the top-left corner while three gene sets are listed along with their five
most significant genes in the top right corner.
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cell adhesion. While there appears to be a considerable
overlap between compounds in components 2, 3 and 10,
the enriched gene sets in component 2 show a strong
link to DNA damage response, 10 is associated with
common cancer signals, and component 3 is associated
with an anabolic response. Components 5 and 6 are
connected to different differentiation events. Compo-
nent 7 links to gene expression changes seen in GPCR
signaling. Component 9 links to amino acid and nitro-
gen metabolism.
We further extracted the significant genes in each
component and performed GO enrichment analysis on
them. Additional file 2: Top_GOTerms.xls shows the
top 10 significant GO terms for each component while
Additional file 3: Top_Genes.xls shows the top 30 sig-
nificantly differentially expressed genes for each.
Based on the Eye diagram (Figure 3) and lists of sig-
nificant genes, gene sets, GO terms, and the top 20 com-
pounds, we summarize the biological and chemical
patterns in Table 1.
Enrichment of known targets
Existing drug response research relies heavily on target
and pathway-based analysis. Our novel approach attempts
to go beyond known targets and pathways to find drug
response groups in an entirely data driven way linkingTable 1 Summarized interpretation of top 10 components. Gr
Comp. Biological Interpretation Compounds in Group A Co
1 Classic growth factor
signaling: (MAP and
protein kinase
signaling)
Sulfonamides, antibiotics,
carbonic anhydrase
inhibitors
An
ant
2 DNA damage Contrast agents, antibiotics, DN
ant
3 Stress response,
mitochondrial and
anabolic metabolism
DNA damaging agents GP
ion
4 Cytoskeleton, cell
adhesion and
migration
GPCR liganda, macrocyclic
cmpds and contrast agents
Bet
oth
5 Differentiation, EMT,
stemness
NSAIDS, cAMP signaling
promoting compounds
HD
6 Inflammatory and
differentiation signaling
N/A Pro
ant
7 GPCR and
cytokine signaling
N/A Car
8 Growth factor and cell
adhesion signaling
Cardiac glycosides β-a
Ca2
9 Amino acid and
nitrogen metabolism
Protein synthesis inhibitors An
10 Cancer signaling DNA damaging agents Co
The pharmacophoric enrichment analysis (marked with “*”) was carried out over Vo
standard, and measuring enrichment of the list in a component by a hypergeometrpharmacophoric descriptors to specific gene expression
response patterns. Some of the found patterns may ra-
tionally be explainable by known targets and next we
analyze the discovered biological process classes (com-
ponents), for enriched protein targets.
We collected a set of drug-protein target pairs from sev-
eral drug databases (see Methods for details); that contains
protein targets for almost half of the CMap drugs. We then
did enrichment analysis of the compounds sharing com-
mon targets in each component (see Methods for details).
The common protein targets and component p-values are
listed in Additional file 6: Target_Breakdown.xls.
As expected, the analysis shows that only few subcom-
ponents have compounds that significantly share protein
targets (p< 0.05). These are 1B, 2B, 10A and 10B. Sub-
component 1B appears to be strongly driven by en-
dogenous amine GPCR interactions. Subcomponent 2B
and 10A, like 3A, are driven by compounds inducing
DNA damage and are discussed below in more detail.
Subcomponent 10B is strongly influenced by glucocorti-
coids primarily targeting the glucocorticoid receptor, but
the fact that several other ion flux modulating com-
pounds (erastin, clofilium tosylate, colforsin, monensin
and lasalocid) also link to this subcomponent argues that
the corticosteroid effects are through the mineralocortic-
oid receptor and that the subcomponent response is
driven by a selected ion flux.oup A and B are the subcomponents of Figure 3
mpounds in Group B VolSurf Interpretation
tipsychotic and
ihistaminic compounds
High lipophilicity
A damaging agents,
imetabolites
Strong lipophilic areas emphasized
CR antagonists,
channel blockers
Polar interactions enriched
a adrenergic agonists,
er GPCR ligands
N/A
AC Inhibitors, HDAC-like Significantly enriched with
pharmacophoric features*
tein synthesis inhibitors,
i-diabetics, cardiac glycosides
Pharmacophoric features*
diac glycosides, cephalosporins Pharmacophoric features*
drenergic agonists,
+ channel blockers
Integy-moment and
significant pharmacophoric enriched*
ti-diabetics Integy-moment and significant
pharmacophoric enriched*
rticosteroids, ionophores Size shape type descriptors
lSurf features (Additional file 5: VolSurf_Classification.xls) considered as a gold
ic test.
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cantly link to target classes in our target analysis is a
strong indicator that the associations between the com-
pounds in most components are not restricted to known
primary target mechanisms and that our method allows
for discovering novel, but still undefined, mechanism of
action and target linkages between compounds. The
evaluation of mechanisms of action that cannot be
explained via known protein targets is a challenging re-
search direction, which requires uncovering the vast hid-
den mechanisms that might make two seemingly non-
similar compounds similar. We feel that our approach
provides a step forward towards the goal of understanding
drug associations extracted from the actual measurement
data that could potentially provide hypotheses for unex-
plored polypharmacology and both target and off-target
drug mechanisms.
Components 3/3A – A cell stress component
We observed that in component 3, the top genes and
gene sets indicate mostly mitochondrial and metabolic
stress-related processes. Top gene sets associating with
this component include many gene sets connecting to
mitochondrial function (Figure 3). Similarly, on the gene
level several known cell stress genes such as PGK1,
PGD, and PRMT1 [15-17] are upregulated. A deeper
look into the 3D structures of the top compounds in this
component (Additional file 1: Top_Compounds.xls)
reveals a possibility of 4–12 hydrogen bonds in all of the
top compounds of set 3A. Thus, these compounds may
be able to affect proton transportation processes, which
is in agreement with the biological interpretation that
mitochondria act like proton pumps. As an example,
Figure 4 shows the hydrogen bond donor and acceptor
regions of azacitidine and idarubicin.
To help understand how the biological variability
caused by the drugs and the chemical features in com-
ponent 3A compares with the intrinsic variability from
one cell type to another, we visualize drug response tran-
sitions on MCF7 cells. Thirty different breast cancer cellFigure 4 Compounds high in hydrogen Bonding. Azacitidine
(left) and Idarubicin (right) showing H-bonding areas with blue
(hydrogen-bond donor) and red (hydrogen-bond acceptor).types are used as references in their unperturbed condi-
tion (as described in Methods). The MCF7 treatments
from subcomponent 3A and the thirty independent
breast cancer cells are plotted in Figure 5 using a recent
multidimensional scaling method called NeRV [18,19].
NeRV shows these different cell instances mapped onto
the 2-dimensional display such that similarities are pre-
served as faithfully as possible. Subcomponent 3A con-
tains many DNA-damaging agents such as the DNA
intercalating and topoisomerase inhibitory camptothe-
cin, daunorubicin, and mitoxantrone, the CDK inhibitors
alsterpaullone, GW-8510 and 0175029–0000, the cardiac
glycoside lanatoside C, which at high concentrations is
likely to inhibit topoisomerases [20] the antimetabolite
methotrexate, as well as rescinnamine, which has been
suggested to induce a DNA damage response without it-
self inducing DNA damage [21] and the aromatase in-
hibitor letrozole. The NeRV plot based on the top
changed genes in treated and untreated MCF7 cells as
well as a panel of other breast cancer cell lines, shows
that after treatment with these drugs, the gene expres-
sion of the luminal, ER-positive MCF7 cells starts to re-
semble the basal, ER-negative breast cancer types.
Interestingly, while MCF7 cells are relatively chromoso-
mally stable, the drug-treatments make them appear like
chromosomally unstable and intrinsic high DNA damage
cell lines such as HCC1937 or MDA-MB-231. Cell stress
is an emerging cancer therapy target and it is interesting
that a) this subcomponent including topoisomerase inhi-
bitors, antimetabolites and CDK inhibitors induces
stress-related metabolic responses in MCF7 cells similar
to what is seen in a basal level in other, more malignantFigure 5 3A drug transitions. NeRV visualization showing Drug
Treatment Transitions. Lines indicate the transition from Pretreated
MCF7 to treated MCF7 cells.
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the hypothesis that the compounds in this subcompo-
nent could be combined with cell stress targeting com-
pounds. This finding is strengthened by the fact that
many of the top upregulated genes in the 3A subcompo-
nent; ACHY, CDC37, GPI, ME2, PMRT1, P4HB, PGD,
and PGK1 are also overexpressed in breast cancers as
compared to normal tissue (Additional file 4: HeatMaps.
pdf, Figure A).
Components 2B & 10A – functionally similar but gene-
wise different responses
We observe that component groups 2B, 3A, and 10A share
several compounds such as the DNA-intercalating topo-
isomerase inhibitors mitoxantrone and irinotecan, the
cyclin-dependent kinase (CDK) inhibitors alsterpaullone,
GW-8510 and 0175029–0000, and the antimetabolites
methotrexate and azacitidine, 5 of the top 20 between each
paired group. Most of the non-overlapping compounds in
each component group are not linked functionally or struc-
turally in any obvious way, on the other hand. To verify that
the components capture different phenomena despite shar-
ing several compounds, we compute chemical composition
and biological similarity matrices over all component pairs.Figure 6 Finding interesting components. Heatmap across the 10 highe
significant genes in each subcomponent, while y-axis represents the top 20
are zoomed in to show the detailed expression pattern along with 3D VolS
water fields). Only a subset (5 compounds and 10 genes) is shown in the zWe use the Tanimoto similarity measure to compute over-
lap between the top 30 genes of each subcomponent pair;
as shown in Additional file 4: HeatMaps.pdf, Figure D. The
analysis of biological similarity between these subcompo-
nents with compound overlap (out of top 20 compounds
for each component) indicates that there is minimal bio-
logical and chemical sharing between any two components.
Almost all component pairs that are highly biologically
similar have a non-significant and low chemical compos-
ition similarity, and vice versa. This is a strong indication
that we have identified sets of VolSurf descriptors that link
to different biological responses. In some cases, several of
these features can be identified in a single molecule like the
etidronic acid, which is linked to both components 3 and 6.
The chemical properties of component 6 are connected
with pharmacophoric features and component 3 with
hydrogen bonding, while biologically the components are
related to differentiation and stress response, respectively.
To get a deeper view of the underlying biological re-
sponse mechanisms we explore the response patterns of
the components using heatmaps. In the first heatmap,
we consider the most active genes in each subcompo-
nent and plot their expression levels across the top
compounds of every subcomponent (Figure 6). In thest scoring significant CCA components: X-axis lists the top 30
scoring compounds in each. Two unique components 2B and 10A
urf descriptors (green areas are the lipophilic fields and the purple
oomed version due to space constraints.
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http://www.biomedcentral.com/1471-2105/13/112figure we search for the subcomponents that have a
unique expression pattern across other subcomponents
in a column. Components 2B and 10A show a unique
structure. These seem to represent two separate aspects
of DNA damage response, which are connected to two
separate molecular features; hydrophobicity in compo-
nent 2B and shape-type VolSurf descriptors in compo-
nent 10A. The gene expression changes in both
subcomponents are strongly linked to a DNA damage
and mitotic arrest response with many proto-oncogenic
cell division and mitogenic signaling genes being down
regulated (Figure 6; Additional file 3: Top_Genes.xls).
The same genes are commonly seen upregulated in can-
cers (Additional file 4: HeatMaps.pdf, Figure B and C)
and many of them have been and are pursued as drug
targets. Therefore both the components are similar on a
larger biological scale, but do in fact have little gene-
wise overlap.
To validate these hypotheses, we checked for reported
growth inhibition for the top 20 chemicals in these two
subcomponents in the NCI/DTP in vitro cell line testing
database (NCI60 testing program, http://dtp.nci.nih.gov/
docs/cancer/cancer_data.html). Four compounds from
2B and 10 from 10A were represented in the NCI60
datasets (Table 2). Almost all of these compounds were
used in CMap at doses that will very effectively stop the
cells from growing or kill them.Table 2 Growth Inhibition verification of 2B/10A
Compounds
Chemical CMap (μM) GI50 (μM) Subcomponent Cell line
berberine 10 25.1 2B MCF7
irinotecan 100 6.3 2B, 10A MCF7
mitoxantrone 7.9 0.004 2B MCF7
amiodarone 6.3 4.0* 2B PC3
8-azaguanine 25.1 0.32 10A HL60
apigenin 15.9 25.1 10A HL60
azacitidine 15.9 0.79 10A PC3
camptothecin 12.6 <0.01** 10A MCF7
chrysin 15.9 15.8*** 10A MCF7
methotrexate 7.9 0.03 10A MCF7
thioguanosine 12.6 0.32 10A MCF7
esculetin 25.1 >100** 10A HL60
fulvestrant 1.0 >100** 10A PC3
GI50 values (drug concentration causing a 50% growth inhibition) from NCI/
DTP are shown along with the corresponding concentrations used in the
Connectivity Map (CMap) data. By comparing the GI50 and CMap values we
can get an idea of expected cell killing effect of the drug in the CMap data.
Drugs that are expected to eventually kill the cells are shown in bold. GI50
and CMap concentration values are in μM scales.
* GI50 value at the end of the tested range.
** Mean of GI50 values from HL60 and MCF7 cell lines.
*** Value from HL60 cell line.Component 7B – A leukemia-specific subcomponent
Based on studying the heatmaps, 7B is another interest-
ing subcomponent: It has a dominant effect on HL60 as
compared to MCF7 and PC3, indicating that this sub-
component and the link between structure and gene ex-
pression may be specific for leukemic cells and leukemic-
specific molecular targets.
Figure 7 shows the activity of most significant genes
(columns) corresponding to the top compounds (rows)
across the three cell lines. The top drugs are mainly car-
diac glycosides and these drugs are known to have a
strong toxic effect on leukemic cells at the concentra-
tions used. It is worth noting that FLT3LG (FLT3 ligand)
is one of the most significantly up-regulated genes. The
FLT3 receptor, to which FLT3LG binds, is an emerging
target in leukemia [22].
Conclusions
We have introduced a chemical systems biology ap-
proach for analyzing the complex relationship patterns
between chemical structures of drug molecules and their
genome-wide responses in cells. With Canonical Correl-
ation Analysis, we are able to find statistical dependencies
between the two data spaces in the form of correlated
components. We have demonstrated quantitatively that
these components are more informative about drug simi-
larity than either chemical or biological data separately.
Our approach finds the relationships in an entirely
data driven way without being constrained to known tar-
get information. Uncovering the detailed mechanisms ofP
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Figure 7 Heatmap for subcomponent 7B. Y-axis lists the top 10
active compounds in the component, replicated over the three cell
lines, while the X-axis lists the most significantly active genes in the
component. The genes are clearly activated systematically and
exclusively in the HL60 cell line, hence indicating an HL60 specific
response.
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having known target classes is a major research goal.
Our approach provides the first step, by generating hy-
potheses for unexplored polypharmacology and both tar-
get and off-target drug mechanisms.
In our study, we used gene sets to introduce biological
knowledge into the analysis. Iorio et al. [8] have recently
got promising results with an alternative method of ana-
lyzing gene expression responses. It is an interesting and
non-straightforward research question whether that ap-
proach can be generalized to searching for structure-
response relationships.
We have also demonstrated the use of advanced
visualization methods to facilitate detailed interpretation
of the chemical and biological characteristics of the
components. Our findings show connections between
the biological responses of many known drug groups to
their general chemical properties (Table 1). As an ex-
ample of the ability of the model to discover detailed
drug response mechanisms we were able to separate dif-
ferent DNA damage responses that appear to be driven
by different chemical features in compound sets having
considerable overlap. Subcomponents 2B, 3A, and 10A
all contain classic chemotherapeutic and DNA damaging
agents as described in the results section. Strikingly, sub-
components 2B and 10A are driven primarily by hydro-
phobic/lipophilic descriptors and are more similar in
their biological output. They both connect to the down-
regulation of many proto-oncogenic and mitotic genes
but notably still through almost entirely non-overlapping
gene sets and genes. Subcomponent 3A, on the other
hand, which is connected to hydrogen bonding and
hydrophilic features, connects to a very different cellular
response: the turning on of many stress-induced
“defense” genes. In other words, we document how
within the same compound or related compounds,
hydrophobic and size features drive a mitotic arrest re-
sponse while hydrogen bonding and hydrophilic features
drive a reparative response. This knowledge, in combin-
ation with gene expression data in the solid tumors may
allow us to design and utilize the chemotherapeutic
agents with the appropriate balance of hydrophilic, size
and hydrogen bonding for each cancer patient to hit the
correct balance between anti-growths to damage re-
sponse induction for best possible efficacy.
Methods
Gene expression data
We used the Connectivity Map gene expression profile
data set as biological response profiles to drug treat-
ments, forming the biological space. Instead of the rank-
based procedure of the original Connectivity Map paper,
we used a different preprocessing method since ranking
amplifies noise; even small differences in low intensities,which contain mostly noise are ranked, and this has a
significant impact on the identification of differentially
expressed genes. Hence, we downloaded the raw data
files in original CEL-format, from http://www.broadinsti-
tute.org/cmap/, which we RMA-normalized [23] before
computing differential expression. We used expression
profiles from the most abundant microarray platform
(HT-HG-U133A) in the data collection and computed
differential expression with respect to the control mea-
surements in each measurement batch. In the case of
multiple controls per batch, we formed a more robust
control by removing as an outlier the control with the
highest Euclidean distance to the other controls, and
then used the mean of the rest as the controls. To fur-
ther reduce noise in the expression data, we discarded
5% of the genes having the highest variance in the con-
trol measurements, that is, genes having high level of
variation unrelated to chemical responses. As simple
means of balancing between the varying sample sizes for
different chemicals in the CMap data, we chose for each
chemical the cell line instance with strongest affect,
measured with the highest norm of response for further
analysis. The resulting gene expression data consisted of
profiles for 1159 compounds over 11,350 genes.
To bring in prior knowledge of biological responses,
and to reduce the dimensionality of the gene expression
data, we performed Gene Set Enrichment Analysis
(GSEA). GSEA gives as output for each gene set the dir-
ection (positive/negative) and strength of the activity, as
measured by the false discovery rate (FDR) q-values,
ranging from 0 (indicating highest activity) to 1. We
transformed the q-values for the CCA by first inverting
such that 1 indicates the highest activity, and then we
further mirrored the interval for the negatively activated
gene sets with respect to zero to take the sign of activity
into account. This results in a reasonably unimodal dis-
tribution of the data around zero, with higher positive
and negative values indicating higher positive and
negative activation of the gene sets, respectively. In the
resulting data we have biological activation profiles
over 1321 gene sets for 1159 distinct chemicals (see
Figure 1B).
As the gene sets, we used the C2 collection (curated gene
sets v2.5) from the Molecular Signatures Database (http://
www.broadinstitute.org/gsea/msigdb/). The extensive col-
lection of gene sets covered 90% genes in our data and is
thus a sensible representation of the biological space. GSEA
was computed with the Java software package version 2–
2.05 (http://www.broadinstitute.org/gsea).
Chemical descriptors
The chemical space was formed by representing each
chemical with a set of descriptors of its structure and
function. In the analysis, the chemical similarity is
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tion is of utmost importance. This is especially true when
the aim is to find small molecules that share targets and
biological functions regardless of structural similarity. We
use the VolSurf descriptors, calculated using MOE version
2009.10 (http://www.chemcomp.com/software.htm). Ori-
ginal sdf-files were translated into 3D using Maestro/
LigPrep (Maestro version 9.0) since VolSurf descriptors
are based on 3D molecular fields. The resulting data con-
tains 76 descriptors for each chemical. Additional file 5:
VolSurf_Classification.xls lists these descriptors.
Canonical correlation analysis
Drug action mechanisms are indirectly visible in relation-
ships between the chemical properties of the drug mole-
cules and the biological response profiles. We carry out a
data-driven search for such relationships with a method
that searches for correlated components in the two spaces,
as shown in Figure 1.
Canonical Correlation Analysis (CCA [9]) is a multivari-
ate statistical model for studying the interrelationships be-
tween two sets of variables. CCA explores correlations
between the two spaces whose role in the analysis is strictly
symmetric, whereas classical regression approaches like
Partial Least Squares [24] typically explain one or possibly
several response variables in one space by a set of inde-
pendent variables in the other one. The result of the CCA
analysis is an underlying component subspace relating
chemical descriptors with gene sets.
Consider two matrices X and Y, of the size of n x p and n
x q, representing the chemical and biological spaces. The
rows represent the samples and the columns are the fea-
tures (gene set activation values or chemical descriptors). In
the following we describe the CCA learning algorithm as a
stepwise process.
First, two projection vectors w1 and v1 are sought such
that they maximize the correlation P1 between compo-
nents of the data,
P1 ¼ max corw1;v1 Xw1;Yv1ð Þ;
subject to the constraint that the variance of the compo-
nents is normalized, i.e.,
var(Xw1) = var(Yv1) = 1.
The resulting linear combinations Xw1 and Yv1 are called
the first canonical variates or components, and P1 is re-
ferred to as the first canonical correlation. The first canon-
ical variates explain the maximum possible shared variance
of the two spaces along a single linear pair of projections:
w1 and v1.
The next canonical variates and correlations can be
found as follows. For each successive step s = 2,3,. . .min(p,q), the projection vectors (ws,vs), can be found by
maximizing
Ps ¼ max corws;vs Xws;Yvsð Þ;
subject to the constraint var(Xws) = var(Yvs) = 1, and with
a further constraint of uncorrelatedness between differ-
ent components.
Let Cxx =XX
T and Cyy = YY
T denote the scaled sample
covariance matrices for the two input spaces, and Cxy =
XYT the sample cross-covariance. Then the first canon-
ical correlation is
P1 ¼ wT1 Cxyv1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
wT1 Cxxw1
q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
vT1 Cyyv1
q
:
If Cxx and Cyy are invertible the vectors w1 and v1
maximizing the above equation can be found. Generally,
in omics data and also in our study, the number of
genes/gene sets is large compared to the number of
experiments. In such cases the classical CCA solution
may not exist or it can be very sensitive to collinearities
among the variables. This issue can be addressed by
introducing regularization [25-27], that penalizes the
norms of the associated vectors. Hence, we seek projec-
tion vectors that maximize the penalized correlation
P1 ¼ wT1 Cxyv1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
wT1 Cxxw1 þ L1‖w1‖
q ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
vT1 Cyyv1 þ L2‖v1‖
q :
The regularization coefficients L1 and L2 were esti-
mated with a 20-fold cross validation over a grid of
values, while maximizing the retrieval performance on
known drug properties. The retrieval procedure and
performance measure are described in the Drug similar-
ity validation section below. In each fold, the model was
first applied to a training data set, and the test data
were then projected to the obtained components. Esti-
mated regularization parameter values were L1 = 100
and L2 = 0.001. We used R-package “CCA” [26].
Drug similarity validation procedure
To quantitatively validate the performance of the
component model in extracting functionally similar
drugs, we carried out the following analysis. For the
given data set, we first computed pairwise similarities
of drugs. In practice, we used each chemical in turn
as a query, and ranked the other chemicals based on
their similarity to the query. For the similarity meas-
ure, we had three alternatives, similarity in the CCA
component space, in the biological space, and in the
chemical space. Finally, we computed the average pre-
cision of retrieving chemicals that are functionally
similar to the query, i.e. share at least one known
property in an external validation set. We report the
mean of the average precisions for all chemicals. We
repeat the analysis as a function of the number of the
Khan et al. BMC Bioinformatics 2012, 13:112 Page 13 of 15
http://www.biomedcentral.com/1471-2105/13/112top ranked chemicals used to compute the average
precision (from 5 to 100).
We constructed the external validation set about the
functional similarity of the drugs from their known
protein targets and ATC (Anatomical Therapeutic
Chemical, http://www.whocc.no/atc_ddd_index/) codes.
Drug target information was obtained from ChEMBL
(https://www.ebi.ac.uk/chembl/), DrugBank (http://www.
drugbank.ca/), DUD (http://dud.docking.org/), and ZINC
(http://zinc.docking.org/). We additionally extracted tar-
gets and ATC codes for the CMap chemicals from the
supplementary material provided in [8]. From the ATC
codes we used the fourth level information, indicating
the chemical/therapeutic/pharmacological subgroup and
hence high similarity of drugs. In total we have 4427
associations between 821 CMap chemicals and 796 tar-
gets or ATC codes.
Visualizing through an “eye diagram”: relationship
between gene sets, extracted components, and VolSurf
descriptors
The CCA components summarize statistical relation-
ships between the chemical and biological spaces. The
relationships can be visualized as in Figure 1 and 3; the
components in the middle are connected to the chem-
ical descriptors that activate them (left) and to the gene
sets (right) that are differentially expressed when the
component is active. We selected the top 10 significant
components from the CCA model for the visualizations.
The significances of the components were estimated by
a permutation test, using the observed correlations as a
test statistic. The samples in one of the spaces were ran-
domly rearranged removing the relationship with the
other space. One thousand such random permutations
were formed and their canonical correlations computed.
Component significances were then determined as the
proportion of random correlations that are greater than
the observed correlation.
The components were further split into two subcom-
ponents labeled ‘A’ and ‘B’, in A the canonical scores are
positive and in B negative. Compounds in the two sub-
components behave in the opposite fashion on the gene
sets and VolSurf features, such that when one of the
subcomponents activates some biological processes, the
other either has no effect or deactivates them. For visual
clarity the eye diagram shows only the top 10 correlated
gene sets for each component, out of the 1321 gene sets
used. All 76 VolSurf features are shown. The eye dia-
gram was originally introduced in [28] for visualizing
component models.
Differentially expressed genes and GO enrichment
To get a comprehensive view of the biology in each
component we extracted the genes and Gene Ontologyclasses active in each one of them. For each component,
we took the top 20 positively and top 20 negatively cor-
related gene sets and listed the genes in them. We then
tested the differential expression of these genes in the
top 10 active compounds in a component using a regu-
larized t-test [29]. The genes having p-values< 0.05
were considered to be significantly activated by the
compounds in the component. This procedure ensures
that the extracted genes are most representative of the
top correlated gene sets in the component, hence con-
tributing the most to the canonical correlation.
The component-specific list of significantly differentially
expressed genes was used to compute the corresponding
Gene Ontology Enrichment for each component. En-
richment was computed for Biological Process classes
using GOstats R-package (www.bioconductor.org/help/
bioc-views/release/bioc/html/GOstats.html). Additional
file 2: Top_GOTerms.xls lists the top 10 significant GO
terms for each component while Additional file 3: Top_-
Genes.xls lists the top 30 significantly differentially
expressed genes.
Target enrichment procedure
The target enrichment analysis of each subcomponent
was performed using the known shared targets. Specific-
ally, the shared targets of top 20 compounds of each sub-
component was compared to target sharing in 1000
random draws of the same number of compounds. P-value
is given by the proportion of enriched targets in the ran-
dom samples. Additional file 6: Target_Breakdown.xls lists
the common targets and p-values for each subcomponent.
Drug Target data was obtained from ChEMBL (https://
www.ebi.ac.uk/chembl/), DrugBank (http://www.drugbank.
ca/), DUD (http://dud.docking.org/), and ZINC (http://
zinc.docking.org/). We additionally extracted targets
from the supplementary material provided in [8]. In
total 716 CMap chemicals had target information.
Characterizing drug response on breast cancer cells
We investigated if the components reveal interesting
patterns in the responses to drugs, by plotting the transi-
tions caused by each drug in the gene subspace defined
by the component. This was done by extracting the 100
most significant genes as an effective representative of
changes caused by treatments in the genome (using the
procedure described in Differentially expressed genes
and GO Terms sub-section above). The profiles of 30 in-
dependent cell lines in a steady-state, unperturbed con-
ditions, were included to act as references for calibrating
the display. These independent breast cancer cell lines
were obtained from ArrayExpress experiment ID E-
MTAB-37 (www.ebi.ac.uk/arrayexpress) with replicates
merged to make a single representation for each of the
cell types. All cell lines were annotated as BasalA,
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Kuemmerle et al.,[30]. Only MCF7 (breast cancer) treat-
ments were used from CMap data.
The breast cancer cell line and CMap data come from
different Affymetrix platforms, HG-U133plus_2.0 and
HT-HG-U133A, respectively. We therefore normalized
them separately by computing differential expression as
the expression value divided by the mean of each gene
within the platform. These normalized data were scaled
using log2.
Both the CMap-selected instances and breast cancer
cell data were collected into a single matrix. To visualize
the transitions, pairwise correlation similarities were
computed over this matrix and plotted using the state-
of-the-art non-linear dimensionality reduction and
visualization tool; Neighbor Retrieval Visualizer NeRV
[18,19]. The result is a mapping of the high-dimensional
expression profiles to a two-dimensional display for eas-
ier visualization, such that if two points are similar in
the visualization, they can be trusted to have been simi-
lar before the projections also. NeRV visualization of
component 3A, which is analyzed in the Results, is
shown in Figure 5.Additional files
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